Astellas Pharma Inc (ALPMY)
Astellas Pharma Inc. is a Japan-based pharmaceutical company whose ordinary shares are represented in the U.S. by an OTC-listed depositary receipt. The company develops, manufactures, markets, imports, and exports prescription medicines in Japan and other international markets. Its portfolio includes oncology treatments such as XTANDI, XOSPATA, VYLOY, and PADCEV, along with products used in areas including ophthalmology, urology, immunology, and women’s health. Additional medicines mentioned by the company include VEOZAH, IZERVAY, EVRENZO, Betanis/Myrbetriq/BETMIGA, and Prograf. Astellas also pursues external innovation through a research collaboration with xFOREST Therapeutics on RNA-targeted therapies and a partnership with Roche Diabetes Care Japan Co., Ltd. on an integrated diabetes self-management solution. Formerly known as Yamanouchi Pharmaceutical Co. Ltd., the company adopted its current name in 2005 and is headquartered in Chuo, Japan.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ALPM.Y
|
$17.20
|
26.5% Upside
|
Undervalued
|
$17.40
|
27.9% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
13.2x
|
2.1x
|
1.8x
|
24.19 B
|
25.481 B
|
14.8%
|
100.0%
|
7.8
|
46.7%
|
172.4%
|
